Brivomax-50 Tablets

Brivomax-50 Brivaracetam 50 mg Tablets

Brivomax-50 Tablets contain Brivaracetam 50 mg, an antiepileptic medicine used in the treatment of partial-onset seizures associated with epilepsy.

Brivaracetam belongs to the antiepileptic class of medicines and is available in an oral tablet formulation. It may be prescribed as monotherapy or as adjunctive therapy depending on the patient's condition, treatment requirements and the prescribing healthcare professional's assessment.

What Are Brivomax-50 Tablets Used For?

Brivomax-50 Tablets are used for the treatment of partial-onset seizures in patients with epilepsy.

Partial-onset seizures, also known as focal seizures, begin in a specific area of the brain. The symptoms can vary depending on the region of the brain involved.

Brivaracetam is specifically indicated for the treatment of partial-onset seizures.

Uses of Brivomax-50

Brivomax-50 may be used for:

• Treatment of partial-onset seizures

• Management of partial-onset seizures associated with epilepsy

• Seizure control as part of an appropriate epilepsy treatment plan

• Monotherapy or adjunctive therapy when prescribed by a qualified healthcare professional

• Management of patients requiring Brivaracetam therapy for partial-onset seizures

Partial-Onset Seizures

Partial-onset seizures originate from a specific area of the brain and are classified as focal seizures.

Their symptoms and clinical presentation can vary depending on the part of the brain involved. Brivaracetam is specifically indicated for the treatment of partial-onset seizures and may be incorporated into an individualized epilepsy treatment plan.

How Does Brivomax-50 Work?

Brivomax-50 contains Brivaracetam, which acts primarily by binding to synaptic vesicle protein 2A (SV2A) in the brain.

This mechanism is associated with modulation of neurotransmitter release and contributes to the antiepileptic activity of Brivaracetam.

Brivaracetam is therefore used to help control partial-onset seizures as part of appropriate epilepsy management.

Role in Epilepsy Management

Epilepsy is a neurological disorder characterized by a tendency to experience recurrent seizures.

Treatment selection depends on factors such as seizure type, age, medical history, concurrent medicines and individual response to treatment.

Brivaracetam is specifically indicated for partial-onset seizures and may be used alone or with other antiepileptic medicines according to medical advice. 

Product Information

Brand Name: Brivomax-50

Composition: Brivaracetam Tablets 50 mg

Active Ingredient: Brivaracetam

Dosage Form: Tablets

Strength: 50 mg

Route of Administration: Oral

Therapeutic Class: Antiepileptic / Anticonvulsant

Therapeutic Area: Neurology

Primary Indication: Partial-Onset Seizures

Packing: 10 x 10 Tablets

Key Product Features

• Contains Brivaracetam 50 mg

• Oral antiepileptic tablet formulation

• Used in the treatment of partial-onset seizures

• Relevant to epilepsy management

• 50 mg strength

• 10 x 10 tablet packing

Important Information

Brivomax-50 is a prescription medicine and should be used only according to the advice of a qualified healthcare professional.

The dosage and treatment duration should be determined according to the patient's clinical condition, response to treatment and tolerability.

Brivaracetam may be used as monotherapy or adjunctive therapy depending on the prescribed treatment plan. 

Patients should not change the prescribed dosage or stop treatment suddenly without consulting their healthcare professional.

Brivaracetam may cause adverse effects such as somnolence, dizziness and fatigue, which may affect alertness. Patients should follow medical advice regarding activities requiring mental alertness. 

Storage

Store the product according to the storage conditions specified on the approved product label.

Keep the medicine out of reach of children.

Product Summary

Brivomax-50 Tablets contain Brivaracetam 50 mg, an antiepileptic medicine indicated for the treatment of partial-onset seizures associated with epilepsy.

Brivaracetam acts primarily through binding to synaptic vesicle protein 2A (SV2A), a mechanism associated with its antiepileptic activity. 

The medicine should be used according to the prescribing information and under the supervision of a qualified healthcare professional.